Criteria of endometrial carcinoma sensitivity to hormone therapy: pathogenetic type of the disease and the tumor reaction to tamoxifen.
The results of assay of receptorial status of tumor in 152 primary patients with endometrial carcinoma are presented. It was shown that a 10-day course of preoperative Tamoxifen therapy (course dose 0.6 g) was able to increase significantly concentrations of nuclear estradiol receptors and cytoplasmatic progesterone receptors in the tumor. This phenomenon followed morphological changes in the tumor and was established in both hormone dependent type (72.7%) and hormone independent type of endometrial carcinoma (45.5%). The assay of the dynamics of receptorial status of primary endometrial carcinoma under influence of Tamoxifen before surgery might be an informative test for selection of sensitive patients with poor prognosis for prolonged hormone therapy in remission to prevent development of recurrencies.
Vishnevsky
A S
AS
Petrov Research Institute of Oncology, St. Petersburg, Russia.
Tsyrlina
E V
EV
Sofroniy
D F
DF
Maximov SJa
Bokhman JaV
Chepick
O F
OF
D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009376:Neoplasms, Hormone-Dependent / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000378:metabolism; D011959:Receptors, Estradiol / Q000096:biosynthesis*; D011980:Receptors, Progesterone / Q000096:biosynthesis*; D013629:Tamoxifen / Q000627:therapeutic use*
D011959:Receptors, Estradiol; D011980:Receptors, Progesterone; D013629:Tamoxifen